Sai Life Sciences FY26 Standalone Profit Surges to Rs. 3,414.81 million
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 14 May 2026, 11:09 PM IST · BSE ID: f4a33432-e57d-4835-b120-1e25471283d7
View Original BSE Filing (PDF)
💡
In Simple Terms
Sai Life Sciences reported its annual financial results, showing a significant increase in profits and revenue compared to the previous year.
🤖 AI Summary
- Sai Life Sciences Ltd. approved audited standalone financial results for the year ended March 31, 2026.
- Revenue from operations for FY26 stood at Rs. 21,532.26 million, up from Rs. 16,420.48 million in FY25.
- Profit for the year ended March 31, 2026, was Rs. 3,414.81 million, compared to Rs. 1,734.62 million in FY25.
- Basic Earnings per equity share for FY26 increased to Rs. 16.27 from Rs. 9.00 in FY25.
- Total assets as of March 31, 2026, were Rs. 36,028.16 million, with total equity at Rs. 25,079.68 million.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Year Ended 31 March 2026)
21,532.26 million
31.13
Profit for the year (Year Ended 31 March 2026)
3,414.81 million
96.86
Basic Earnings per equity share (Year Ended 31 March 2026)
16.27
80.78
Total Income (Year Ended 31 March 2026)
22,023.57 million
31.14
Total Assets (As at 31 March 2026)
36,028.16 million
🏢 How This Affects the Company
The company's revenue from operations increased to Rs. 21,532.26 million in FY26, indicating growth in its core business activities.
Profit for the year ended March 31, 2026, nearly doubled to Rs. 3,414.81 million, improving overall profitability and earnings per share.
Capital work-in-progress significantly increased to Rs. 2,704.53 million, suggesting ongoing investments in expanding operational capacity.
Non-current borrowings increased to Rs. 205.04 million in FY26, which impacts the company's long-term debt structure.
👥 What This Means For Shareholders
✅
Action Required
No immediate action required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the improved financial performance, with Basic EPS increasing to Rs. 16.27 for FY26 from Rs. 9.00 in FY25.
🔍
Management Signal
The Board's approval of the audited financial results signals management's formal disclosure of the company's annual performance.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 results — observe revenue and profit growth trend.
Future capital expenditure filings — assess ongoing investment in capacity.
Analyst calls/presentations — gain insights into management's outlook.
LOW RISK
No specific new risks or material adverse events identified in the financial results.
💡 Investor Takeaway
Sai Life Sciences Ltd. reported audited standalone financial results for FY26. Revenue from operations increased to Rs. 21,532.26 million (31.13% YoY). Profit for the year surged to Rs. 3,414.81 million (96.86% YoY). Basic EPS stood at Rs. 16.27.
⚖️ Strengths & Concerns
✅ Positives
- Revenue from operations grew to Rs. 21,532.26 million in FY26, up from Rs. 16,420.48 million in FY25, indicating strong top-line expansion.
- Profit for the year ended March 31, 2026, nearly doubled to Rs. 3,414.81 million from Rs. 1,734.62 million in FY25, reflecting enhanced profitability.
⚠️ Concerns
- Cash and cash equivalents decreased to Rs. 786.04 million as of March 31, 2026, from Rs. 851.92 million in the prior year.
- Other bank balances saw a substantial decrease to Rs. 289.57 million from Rs. 3,727.63 million in the previous year.
📅 Company Track Record
On May 14, 2026, Sai Life Sciences announced a 96.86% surge in FY26 net profit to Rs. 3,414.81 million, following a board meeting scheduled to approve results. This continues a trend of significant financial performance disclosures.
Based on publicly available historical data. For context only.